<DOC>
	<DOCNO>NCT00679081</DOCNO>
	<brief_summary>The purpose study evaluate CelTx alternative tissue palate treatment subject Miller Class I II recession defect desire root coverage . It anticipate study demonstrate CelTx safe alternative palatal tissue demonstrate potential enhance oral soft tissue regeneration wound healing .</brief_summary>
	<brief_title>A Pilot Study CelTx ( TM ) ( Apligraf® ) Treatment Gingival Recession Requiring Root Coverage</brief_title>
	<detailed_description />
	<mesh_term>Gingival Recession</mesh_term>
	<criteria>Subject least 18 year age 70 year age . Subject least two nonadjacent teeth contralateral quadrant jaw Miller Class I II buccal recession ( ≥ 3 mm ) require soft tissue grafting . ( Teeth may treat maximum difference 2 mm respect depth width ) . Females childbearing potential must document negative urine pregnancy test must agree continue acceptable method contraception 6 month post surgery . Subjects must read , understood sign institutional review board ( IRB ) approve Informed Consent Form ( ICF ) . Subjects must able willing follow study procedure instruction . Subject extremely prominent root surface ( &gt; 1/2 diameter root facial cortical plate ) . Subject interproximal attachment loss beyond CEJ . Subject teeth Miller Grade 2 high mobility . Subjects Class V restoration . Subjects crown teeth select treatment . Subjects endodontic therapy last 6 month teeth select treatment . Subjects use tobacco product within past 3 month . Subjects molar teeth suitable soft tissue graft . Subject probe pocket depth &gt; /= 4 mm either surgical site . Female subject pregnant lactating . Subjects systemic condition ( i.e. , uncontrolled diabetes mellitus , cancer , HIV , bone metabolic disease ) could compromise wound heal preclude periodontal surgery . Subjects currently receive receive within two month prior study entry , systemic corticosteroid , immunosuppressive agent , radiation therapy , and/or chemotherapy could compromise wound heal preclude periodontal surgery . Subjects presence acute infectious lesion . Subjects take intramuscular intravenous bisphosphonates . Subjects know hypersensitivity bovine collagen and/or iodine ( shellfish allergy ) . Subjects received investigational drug , device biological/bioactive treatment within 30 day prior study enrollment ( medical dental ) . Subjects previously treat Apligraf/CelTx , Dermagraft cellbased product , include autologous tissue target site ( ) immediately adjacent teeth . Subjects , opinion investigator , reason list , able complete study per protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>